Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.

Yoo JY, Haseley A, Bratasz A, Chiocca EA, Zhang J, Powell K, Kaur B. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther. 2012 Feb; 20(2):287-97.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.